Takeda – Talk Bio

Takeda and Innovent Forge $1.2B Upfront Oncology Pact for Bispecific and ADC Therapies, Total Deal Valued Up to $11.4B

4 days ago talkbio0Tagged Antibodies, Bispecific, Antibody-Drug Conjugates, Cancer Therapeutic Procedure, co-development, global strategic partnership, IBI343, IBI363, Innovent Biologics, Neoplasms, Payments, Takeda

Takeda; Innovent Biologics; global strategic partnership; bispecific antibody; antibody-drug conjugate (ADC); oncology; IBI363; IBI343; IBI3001; $1.2 billion upfront; $11.4 billion total deal; cancer therapy; co-development; milestone payments

Takeda Expands De Novo Protein Research with Second AI-Driven Collaboration with Nabla Bio

2 weeks ago talkbio0Tagged AI drug discovery, antibody design, biopharmaceutical innovation, De Novo, JAM, Joint Atomic Model, multi-year collaboration, Nabla Bio, Takeda, therapeutic protein

Takeda; Nabla Bio; de novo protein design; AI drug discovery; Joint Atomic Model (JAM); multi-year collaboration; protein therapeutics; antibody design; biopharmaceutical innovation

Takeda to Cut 137 Staffers After Exiting Cell Therapy Research

3 weeks ago talkbio0Tagged Cell Therapy, Exit, Industry, layoffs, Massachusetts (geographic location), pipeline shake-up, portfolio reprioritization, R&D, restructuring, strategic, Takeda

Takeda; layoffs; cell therapy exit; biotech industry; restructuring; Massachusetts R&D; strategic portfolio reprioritization; pipeline shake-up

Curtain Closes on Takeda’s Cell Therapy Efforts

3 weeks ago talkbio0Tagged Biological Factors, Cell Therapy, Gamma/Delta T-Lymphocyte, Impaired, research discontinuation, strategic shift, Takeda

Takeda; cell therapy; research discontinuation; impairment loss; gamma delta T-cell; strategic shift; biopharmaceuticals

Takeda and Alkermes Detail Strong Clinical Results for Orexin Drugs in Narcolepsy – Head-to-Head Race Accelerates

2 months ago talkbio0Tagged agonists, alixorexton, Alkermes, Cataplexy, Clinical Trials, Daytime Somnolence, Excessive (qualifier value), Maintenance, MWT, Narcolepsy, orexins, oveporexton, Phase 3, Takeda, Wakefulness Test

Takeda; Alkermes; orexin agonists; narcolepsy; oveporexton; alixorexton; clinical trials; Phase 3; excessive daytime sleepiness; cataplexy; maintenance of wakefulness test (MWT)

Takeda’s Phase 3 Success Positions Oveporexton (TAK-861) as Potential First Mover in Multibillion-Dollar Narcolepsy Market

2 months ago talkbio0Tagged Clinical Trials, multibillion-dollar market, Narcolepsy type 1, oveporexton, Phase 3, Standard of Care, TAK-861, Takeda, TPRG1L gene

Takeda; Phase 3; narcolepsy type 1; oveporexton; TAK-861; orexin agonist; multibillion-dollar market; clinical trial results; first mover; standard of care

Takeda’s Oveporexton Succeeds in Two Phase III Trials, Paving Way for Narcolepsy Drug Filings

3 months ago talkbio0Tagged Clinical Trials, File (record), Narcolepsy, Narcolepsy type 1, orexin agonist, oveporexton, Phase 3 Clinical Trials, Takeda, United States Food and Drug Administration

Takeda; Oveporexton; narcolepsy; Phase III trials; orexin agonist; FDA filing; Narcolepsy Type 1; clinical trial results

FDA Approves CSL’s Andembry, Directly Competing With Takeda’s Takhzyro in HAE

4 months ago talkbio0Tagged Andembry, Angioedemas, Hereditary, Approved, dosing, factor XIIa, garadacimab-gxii, Inhibitor, SMPX gene, Subcutaneous Injections, Takeda, Takhzyro, United States Food and Drug Administration

Andembry; garadacimab-gxii; FDA approval; hereditary angioedema; HAE; CSL; Takhzyro; Takeda; factor XIIa inhibitor; once-monthly dosing; subcutaneous injection